Good
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI assertions about leucovorin terminology are generally consistent with the label framing for VYKOURA (leucovorin/folinic acid naming), but the response includes claim-assessment text beyond the actual FDA label excerpts shown and marks mixing/compatibility as absent without providing the complete label sections needed to verify that absence. The only clearly label-supported items in the supplied excerpts concern IV rate limits and avoidance of intrathecal administration.
Category Scores
Accurate Statements
A maximum intravenous administration rate of 160 mg per minute (16 mL per minute) for VYKOURA is required to avoid hypercalcemia.
Supported by provided label excerpt 2.6: “Do not exceed an intravenous administration rate of 160 mg per minute (16 mL per minute) to avoid hypercalcemia [see Warnings and Precautions (5.2)].”
Do not administer more than 160 mg of VYKOURA intravenously per minute due to calcium content/hypercalcemia risk.
Supported by provided label excerpt 5.2: “do not administer more than 160 mg of VYKOURA intravenously per minute [see Dosing and Administration (2.6)].”
Do not administer VYKOURA intrathecally; it may be harmful or fatal if given intrathecally.
Supported by provided label excerpt 5.3: “do not administer VYKOURA intrathecally. VYKOURA MAY BE HARMFUL OR FATAL IF GIVEN INTRATHECALLY.”
Unsupported Statements
Statements about mixing/compatibility (e.g., precipitate or incompatibility if co-administered via the same IV line) are not substantiated by the provided label excerpts.
The response concludes that mixing/compatibility guidance is absent based only on the provided excerpt set; absence cannot be confirmed from partial excerpts.
The response text claims the mixing/compatibility/precipitate issue was “not found in the provided excerpts,” and uses that to characterize the label support level for the mixing/compatibility component.
Label-support determination is contingent on the completeness of the provided label sections; the excerpt set may be incomplete.
Contradictions
Important Omissions
The response does not explicitly cite or verify the provided label excerpt for contraindications/hypersensitivity (Section 4) even though it appears in the supplied label context for a comprehensive safety assessment.
Importance:
Low
The response does not assess boxed warnings, adverse reactions, or specific population sections because those label excerpts were not provided; however it also characterizes overall label alignment without addressing these potentially material areas.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only concrete clinical administration safety points evaluated (IV rate limit and prohibition of intrathecal administration) align with the provided excerpts. The main gap is overconfidence regarding the nonexistence of mixing/compatibility guidance from incomplete excerpt coverage.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Over-reliance on excerpt incompleteness to judge label absence for mixing/compatibility guidance.
Suggested Improvement
Limit “unsupported/absent” determinations for mixing/compatibility strictly to the provided excerpt set and avoid implying the label contains no such information unless the full relevant label sections are provided.